Sigma-Aldrich Announces the Aqua Peptide™ Partnership Program and Launch of the World's First Aqua Peptide Library
News Jun 05, 2007
Sigma-Aldrich has announced the launch of the AQUA (Absolute Quantitation) Peptide Partnership Program, where Proteomic researchers ordering custom AQUA Peptides from Sigma-Aldrich will be invited to join the world's first AQUA Peptide Partnership Program.
In addition, sequences of their AQUA Peptides will be added to Sigma-Aldrich's growing AQUA Peptide Library, and contributors will receive partnership pricing on their custom orders.
Initially developed in collaboration with the Protein Quantitation Consortium, Sigma-Aldrich's AQUA Peptide Library will contain hundreds of AQUA Peptides.
Protein-AQUA™, a strategy first presented by Dr. Steve Gygi at the Harvard Medical School, enables focused, quantitative mass spectrometric studies of not only specific protein biomarkers, but specific amino acid modifications as well. In addition, the Protein-AQUA technique enables validation of gene silencing at the protein level via mass spectrometry.
"We clearly recognize the need within the Proteomics community for a sizable library of stable-isotope labeled tryptic peptides, and we look forward to partnering with our customers to make that library a reality," said Jennifer Williams, Sigma-Aldrich product manager for quantitative proteomics.
"The AQUA Peptide Partnership Program exemplifies our commitment to providing cutting-edge proteomics tools to the research community and to the development of innovative products in order to progress scientific research," Williams added.
"The AQUA Technology enables scientists to focus their protein biomarker research as they progress from biomarker discovery to biomarker validation, and the ideal tool is an AQUA peptide," said Dale Peluso, Sigma-Aldrich market segment manager for quantitative proteomics.
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.